FEB 14, 2020 5:48 AM PST

Rewired natural killer cells show promising results in leukemia patients

WRITTEN BY: Tara Fernandes

Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrating host-rejection responses against both cancer cells and virally infected cells. Cancer researchers and drug developers are supercharging NK cells to attack malignant tissues by engineering them to express chimeric antigen receptors (CAR) in a process similar to FDA-approved T cell therapies Yescarta and Kymriah.

In a recent study published in The New England Journal of Medicine, clinical trial data shows promising results in patients with non-Hodgkin’s lymphoma or chronic lymphocytic leukemia that were treated with anti-CD19 CAR NK cells.

Significantly, the treatment was found to be effective while not triggering the flare-up of a common side effect of this type of adoptive immune cell therapy: cytokine release syndrome. 

This systemic inflammatory response, also known as an infusion reaction, is an unwanted complication that occurs when large numbers of activated immune cells are injected into a patient. Symptoms include seizures, fever, nausea, and in serious cases, cytokine release syndrome may even cause fatalities.

In the early data reported from this phase I/II trial, 73 percent of patients showed a positive response to the CAR NK therapy, with the majority of responding patients showing signs of complete remission. These responses occurred within a month after the cell therapy was administered, with CAR NK cells showing signs of persistence in the infused patients up to a year post-treatment.

Corresponding author, Katy Rezvani, MD, Ph.D., professor of stem cell transplantation and cellular therapy at The University of Texas MD Anderson Cancer Center said, “We are encouraged by the results of the clinical trial, which will launch further clinical studies to investigate allogeneic cord blood-derived CAR NK cells as a potential treatment option for patients in need.”

 

Sources: Cancer Network, The New England Journal of Medicine.

 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
JUN 14, 2022
Coronavirus
Advances in Latest Coronavirus Research in the 2022 Ongoing Labroots Virtual Event Series
JUN 14, 2022
Advances in Latest Coronavirus Research in the 2022 Ongoing Labroots Virtual Event Series
Labroots hosted its 3rd annual Coronavirus Conference Virtual Event Series on May 4, 2022. The speaker roster for this f ...
JUN 15, 2022
Drug Discovery & Development
High Intensity Ultrasound Therapy Treats Localized Prostate Cancer
JUN 15, 2022
High Intensity Ultrasound Therapy Treats Localized Prostate Cancer
High-intensity-focused ultrasound (HIFU) can treat some men with prostate cancer instead of surgery or radiation therapy ...
JUL 02, 2022
Health & Medicine
How Healthy Is Your Diet?
JUL 02, 2022
How Healthy Is Your Diet?
Is your diet as healthy as you think it is? Probably not - I know mine isn't. Recent research has revealed that ...
JUL 16, 2022
Microbiology
Breastmilk Can Reduce Infection Risk, with a Tradeoff
JUL 16, 2022
Breastmilk Can Reduce Infection Risk, with a Tradeoff
Breastfeeding is encouraged because it provides many benefits to both mothers and infants. Breastmilk is nutritious, and ...
AUG 16, 2022
Health & Medicine
In Transplant Breakthrough, the Blood Type of a Donor Kidney is Changed
AUG 16, 2022
In Transplant Breakthrough, the Blood Type of a Donor Kidney is Changed
Blood types have to be considered when a person is receiving a kidney transplant. An individual with type A blood, for e ...
SEP 01, 2022
Clinical & Molecular DX
A Common Bacterial Infection Could Lead to Colon Cancer
SEP 01, 2022
A Common Bacterial Infection Could Lead to Colon Cancer
Infections of the bacterium C. difficile can cause diarrhea and inflammation of the colon called colitis. It is estimate ...
Loading Comments...